Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved…
The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral…
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes…
Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report…
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s…
Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention…